e-ISSN: Pending
Negative / Null Result ReportOpen accessBiochemistry, Genetics and Molecular Biology· cited by 10

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Victoria Bae‐Jump; Michael W. Sill; Paola A. Gehrig; Jason D. Merker; David L. Corcoran; Adam D. Pfefferle; Michele C. Hayward; Joan L. Walker · 2025 · Gynecologic Oncology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract (excerpt)

INTRODUCTION: We evaluated the efficacy of the addition of the anti-diabetic drug metformin to standard-of-care paclitaxel and carboplatin (PC) in patients with advanced and recurrent endometrial cancer (EC). METHODS: In this phase II/III…

Excerpt shown for reference under fair use — read the full paper at the publisher.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1016/j.ygyno.2025.03.003